#076: Alemtuzumab (Lemtrada, Campath) For Highly Active Relapsing MS MS-Perspektive

MS-Perspektive - The Multiple Sclerosis Podcast « »

#076: Alemtuzumab (Lemtrada, Campath) for highly active relapsing MS

17d ago 27:06

内容由Nele Handwerker提供。所有播客内容（包括剧集、图形和播客描述）均由 Nele Handwerker 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.

You can read the full article on my blog: https://ms-perspektive.com/076-alemtuzumab

This time the focus is on alemtuzumab (Lemtrada, Campath). It is one of the highly effective immunotherapies and, in a subgroup of patients with highly active MS, even enables disease activity to be halted for more than five years. Due to its long-lasting effects on the immune system and sometimes severe side effects, it is used relatively sparingly.

It is used as a disease-modifying therapy for active multiple sclerosis, both in relapsing forms and, following FDA approval, also in active SPMS.

Due to its mechanism of action, alemtuzumab leads to immediate immune cell depletion of CD52-positive immune cells (primarily T cells and B cells). It is therefore used, for example, in patients with massive inflammatory activity who are at risk of a rapid increase in disability.

Please remember that I can only provide an overview here. Your neurologist and your MS nurse should advise you in detail about the right therapy for you. This is because they know your general state of health and you should also talk about your goals, wishes, fears and preferences so that these can be taken into account.

Table of Contents

Sources

I used the following sources to create the content:

---

You may also want to look at the posts on the other DMTs:

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.